je.st
news
Home
› Premarket Biotech Digest: Gilead's Upcoming Earnings, Setback For AstraZeneca, Zafgen Tumbles 50%
Premarket Biotech Digest: Gilead's Upcoming Earnings, Setback For AstraZeneca, Zafgen Tumbles 50%
2015-10-19 16:04:07| Biotech - Topix.net
The consensus forecast for Q3 revenue is at $7.81 billion, which is below the $8.24 billion reported in the previous quarter. The slight decline in revenue is due to a slowdown in the U.S. Hep C sales.
Tags: upcoming
earnings
digest
biotech
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||